{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:14Z","timestamp":1772119454553,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00520-023-07776-6","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T04:01:27Z","timestamp":1682913687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, predictors, and outcomes of febrile neutropenia and neutropenia in patients with metastatic castrate-resistant prostate cancer receiving docetaxel"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-5166","authenticated-orcid":false,"given":"Sophie","family":"Peltekian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-8964","authenticated-orcid":false,"given":"Shellyza","family":"Sajwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-0360","authenticated-orcid":false,"given":"Salmaan","family":"Kanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"7776_CR1","unstructured":"(2021) NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed November 14th, 2022"},{"key":"7776_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512. https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"key":"7776_CR3","unstructured":"(2021) Cancer Care Ontario drug monograph: docetaxel. https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/docetaxel. Accessed November 14th, 2022"},{"key":"7776_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.6004\/jnccn.2003.0038","volume":"1","author":"DC Dale","year":"2003","unstructured":"Dale DC, McCarter GC, Crawford J et al (2003) Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 1:440\u2013454. https:\/\/doi.org\/10.6004\/jnccn.2003.0038","journal-title":"J Natl Compr Canc Netw"},{"key":"7776_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","volume":"15","author":"AJ Zimmer","year":"2019","unstructured":"Zimmer AJ, Freifeld AG (2019) Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 15:19\u201324. https:\/\/doi.org\/10.1200\/JOP.18.00269","journal-title":"J Oncol Pract"},{"key":"7776_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/jjco\/hyz051","volume":"49","author":"T Kosaka","year":"2019","unstructured":"Kosaka T, Uemura H, Sumitomo M et al (2019) Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol 49:766\u2013771. https:\/\/doi.org\/10.1093\/jjco\/hyz051","journal-title":"Jpn J Clin Oncol"},{"key":"7776_CR7","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"key":"7776_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"7776_CR9","unstructured":"Crespo A, Forbes L, Vu K et al (2021) Prevention and outpatient management of febrile neutropenia in adult cancer patients: clinical practice guideline. https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/38561. Accessed November 14th, 2022"},{"key":"7776_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","volume":"19","author":"W Hosmer","year":"2011","unstructured":"Hosmer W, Malin J, Wong M (2011) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19:333\u2013341. https:\/\/doi.org\/10.1007\/s00520-010-0821-1","journal-title":"Support Care Cancer"},{"key":"7776_CR11","doi-asserted-by":"crossref","unstructured":"Kongsted P, Svane IM, Lindberg H et al (2016) Predictors of chemotherapy-induced toxicity and treatment outcomes in elderly versus younger patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 14:e559-e568. S1558\u20137673(16)30072\u20136","DOI":"10.1016\/j.clgc.2016.03.018"},{"key":"7776_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10147-014-0746-7","volume":"20","author":"K Shigeta","year":"2015","unstructured":"Shigeta K, Kosaka T, Yazawa S et al (2015) Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol 20:605\u2013612. https:\/\/doi.org\/10.1007\/s10147-014-0746-7","journal-title":"Int J Clin Oncol"},{"key":"7776_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2310\/JIM.0b013e3181cf9002","volume":"58","author":"HH Chao","year":"2010","unstructured":"Chao HH, Mayer T, Concato J et al (2010) Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy. J Invest Med 58:566. https:\/\/doi.org\/10.2310\/JIM.0b013e3181cf9002","journal-title":"J Invest Med"},{"key":"7776_CR14","unstructured":"(2017) Common Terminology Criteria for Adverse Events Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed November 14th, 2022"},{"issue":"5","key":"7776_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ajco.12840","volume":"14","author":"AA Hamid","year":"2018","unstructured":"Hamid AA, Willson K, Vincent AD et al (2018) Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer. Asia Pac J Clin Oncol 14(5):399\u2013404. https:\/\/doi.org\/10.1111\/ajco.12840","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07776-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07776-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:13:53Z","timestamp":1684214033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07776-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7776"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07776-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2281655\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research Ethics Board approval was obtained from the Ottawa Hospital Research Institute with a waiver of consent prior to study commencement (REB #20210171-01H).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}